'On consolidated basis
Quarter ended September 2024 compared with Quarter ended September 2023.
Net sales (including other operating income) of Natco Pharma has increased 32.94% to Rs 1371.1 crore.
Profit before interest, tax and other unallocable items (PBIT) has jumped 85.29% to Rs 822.30 crore.
Overall PBIT margin rose from 43.03% to 59.97%.
Operating profit margin has jumped from 44.41% to 58.66%, leading to 75.61% rise in operating profit to Rs 804.30 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 16.27% to 10.30%. Purchase of finished goods cost fell from 4.01% to 3.86%. Employee cost decreased from 11.96% to 10.90%. Other expenses fell from 22.99% to 17.10%.
Other income rose 117.01% to Rs 63.8 crore. PBIDT rose 78.11% to Rs 868.1 crore. Provision for interest fell 2.38% to Rs 4...
Pleaselogin & subscribe to view the full report.
More Reports
-
-
Capex for the quarter was Rs 2,857 crore
-
(31-Jan-2025)
GAIL (India)
-
|
|